Back to top
more

Merck KGaA (MKGAF)

(Delayed Data from OTC)

$183.88 USD

183.88
81

-2.12 (-1.14%)

Updated Sep 9, 2024 03:45 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value F Growth B Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 39% (98 out of 249)

Industry: Medical - Drugs

Better trading starts here.

Zacks News

Indrajit Bandyopadhyay headshot

Merck KGaA (MKGAF) Q2 Earnings Down Y/Y, Sales Flat

Merck KGaA (MKGAF) reports a mixed second-quarter with earnings declining year-over-year while sales remaining flat.

    What's in the Cards for Merck KGaA (MKGAF) in Q2 Earnings?

    Merck's (MKGAF) Healthcare and Life Science segments are expected to drive sales in Q2. However, higher operating expense to support Bavencio and Mavenclad launch is expected to weigh on performance.

      Juniper Inks Deal to be Acquired by Catalent, Shares Up

      Juniper Pharmaceuticals, Inc. (JNP) inks a deal with Catalent, Inc. Per the deal, Catalent will acquire all of the outstanding shares of Juniper at a price of $11.50 per share in cash.

        Merck KGaA (MKGAF) Q1 Earnings and Revenues Decline Y/Y

        Merck KGaA (MKGAF) reports dismal first-quarter results with earnings declining year over year. Revenues fall due to continued negative currency movement.

          What's in the Cards for Merck KGaA (MKGAF) in Q1 Earnings?

          Merck's (MKGAF) Healthcare and Life Science segments to drive sales in Q1. However, operating expense is expected to be higher to support the launch of Bavencio and Mavenclad.

            Pfizer's Kidney Cancer Drug Misses Endpoint in Phase III

            Pfizer's (PFE) kidney cancer drug Inlyta (axitinib) fails to demonstrate a clear improvement in the primary endpoint of extending disease-free survival (DFS) in a late-stage study.

              Merck KGaA's Tepotinib Gets Fast Track Designation in Japan

              Merck KGaA's (MKGAF) lung cancer candidate, tepotinib gets fast track designation in Japan.

                Indrajit Bandyopadhyay headshot

                Merck KGaA (MKGAF) Q4 Earnings Flat Y/Y, Sales Up

                Merck KGaA (MKGAF) reports a mixed fourth-quarter with earnings remaining flat year-over-year while sales is up.

                  What's in the Cards for Merck KGaA (MKGAF) in Q4 Earnings?

                  Merck's (MKGAF) Healthcare and Life Science segments are likely to drive sales in Q4. However, the company's oncology drug fails in a phase III gastric cancer study.

                    Vertex (VRTX) Q4 Earnings Beat on Strong CF Products Sales

                    Vertex Pharma (VRTX) fourth-quarter earnings increase from the year-ago period led by strong sales of CF drugs and lower operating expenses.

                      Roche MS Drug Ocrevus Gets Marketing Authorization in Europe

                      Roche's (RHHBY) multiple sclerosis drug Ocrevus gets approval in Europe thereby boosting its neuroscience portfolio. The drug is already approved in the United States.

                        Pfizer/Merck KGaA's Bavencio Fails in Gastric Cancer Study

                        Pfizer & Merck KGaA's (MKGAF) Bavencio/avelumab fails in a phase III study evaluating it for the treatment of gastric cancer in the third-line setting.

                          Orexigen (OREX) Q3 Loss Narrower Than Expected, Stock Up

                          Orexigen (OREX) reported a narrower-than-expected loss on higher Contrave volumes.

                            Merck KGaA (MKGAF) Q3 Earnings Decline Y/Y, Revenues Flat

                            Merck KGaA (MKGAF) reported dismal third-quarter results with earnings declining year over year. Revenues were flat amid continued negative currency movement.

                              Merck KGaA (MKGAF) Q3 Earnings Down Y/Y, Sales Flat

                              Merck KGaA (MKGAF) reports a challenging third-quarter with earnings down year-over-year and sales remaining flat.

                                What's in the Cards for Merck KGaA (MKGAF) in Q3 Earnings?

                                Merck's (MKGAF) Healthcare and Life Science segments are expected to drive third-quarter sales. The company is progressing with its oncology drug, Bavencio and is also focusing on streamlining its business.

                                  Indrajit Bandyopadhyay headshot

                                  Merck KGaA (MKGAF) Q2 Earnings Up Y/Y

                                  Merck KGaA (MKGAF) reports second-quarter results with earnings rising year-over-year and sales registering organic growth.

                                    What's in the Cards for Merck KGaA (MKGAF) in Q2 Earnings?

                                    Merck KGaA???s (MKGAF) Life Science segment is expected to perform well following the approval of Bavencio.

                                      Merck KGaA (MKGAF) Q1 Earnings Fall Y/Y, Revenues Increase

                                      Merck KGaA (MKGAF) reported first-quarter 2017 earnings of $1.28 per American Depositary Share, 14.7% lower than the year-ago figure of $1.50.

                                        Indrajit Bandyopadhyay headshot

                                        Merck KGaA (MKGAF) Q1 Earnings Down Y/Y, 2017 View Updated

                                        The company???s first-quarter 2017 earnings per American Depositary Receipt (ADR) came in at $1.28, compared to the year-ago figure of $1.50

                                          What's in Store for Merck KGaA (MKGAF) in Q1 Earnings?

                                          Merck KGaA (MKGAF) is scheduled to report first-quarter 2017 earnings results on May 18.

                                            What's in Store for Merck KGaA (MKGAF) in Q4 Earnings?

                                            Merck KGaA (MKGAF) is scheduled to report fourth-quarter 2016 earnings results on Mar 9.

                                              Is BioMarin (BMRN) Well Poised for Growth in 2017?

                                              We issued an updated research report on BioMarin Pharmaceutical Inc. (BMRN) on Jan 25.

                                                Merck KGaA, Vertex Announce Tie-Up for Oncology Programs

                                                Merck (MKGAF) and Vertex (VRTX) collaborated for the development and commercialization of four research and development programs for the treatment of cancer.

                                                  BioMarin (BMRN) Raised to Buy: Should You Add the Stock?

                                                  The Zacks Investment Research upgraded BioMarin (BMRN) to a Zacks #2 Rank (Buy).